April 15 (Reuters) - Avinger Inc AVGR.O :
* AVINGER - REVENUE IN Q1 2020 IS EXPECTED TO BE
APPROXIMATELY
$2.25 MILLION, UP 22%
* AVINGER - EXPECTS A DECLINE IN OVERALL CASE VOLUME AND
SALES OF
ITS PRODUCTS TO CONTINUE THROUGH Q2 2020
* AVINGER - IMPLEMENTED SERIES OF COST REDUCTIONS IN Q2,
INCLUDING
20% SALARY REDUCTION COMPANY-WIDE
* AVINGER - IMPLEMENTED SERIES OF COST REDUCTIONS IN Q2,
INCLUDING
REDUCTION IN HOURS WORKED BY MANUFACTURING AND OTHER HOURLY
EMPLOYEES
* AVINGER - IMPLEMENTED SERIES OF COST REDUCTIONS IN Q2,
INCLUDING
DISCRETIONARY SPENDING CUTS ACROSS THE ORGANIZATION
* AVINGER - CONTINUES TO ADVANCE KEY PRODUCT DEVELOPMENT
PROGRAMS,
DOES NOT EXPECT TIMELINES FOR THESE PROGRAMS TO BE IMPACTED BY
COVID-19
* AVINGER - IN RESPONSE TO COVID-19 PANDEMIC, ADDITIONAL
PATIENT
ENROLLMENT AND SITE INITIATION HAS BEEN PAUSED FOR IMAGE-BTK
STUDY
Source text: [https://bit.ly/2yfaTZC]
Further company coverage: AVGR.O
((Reuters.Briefs@thomsonreuters.com;))